stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) Return on assets
Rhythm Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 September 2026 was −41.8%, up 4.5 percentage points from fiscal 2025 (−46.3%). Over the past ten years it has ranged from −117.2% (fiscal 2016) to −27.0% (fiscal 2021); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −46.3% | 26.69 |
| FY2024 | −73.0% | (21.34) |
| FY2023 | −51.6% | (0.76) |
| FY2022 | −50.9% | (23.93) |
| FY2021 | −27.0% | 27.12 |
| FY2020 | −54.1% | (4.58) |
| FY2019 | −49.5% | (13.53) |
| FY2018 | −36.0% | 9.85 |
| FY2017 | −45.8% | 71.39 |
| FY2016 | −117.2% | (68.83) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| CORT Corcept Therapeutics Incorporated compare | 17.2% |
| ORKA Oruka Therapeutics, Inc. compare | −17.8% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −18.3% |
| IONS Ionis Pharmaceuticals, Inc. compare | −18.9% |
| AXSM Axsome Therapeutics, Inc. compare | −21.0% |
| PRAX Praxis Precision Medicines, Inc. compare | −36.8% |
| RYTM Rhythm Pharmaceuticals, Inc. | −41.8% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| ABVX Abivax SA Sponsored ADR compare | −137.7% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement